Board of Directors

For the past two decades, Paul has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals and Gilead.

He has also provided financial leadership and business development for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales. Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market. Additionally, his other corporate responsibilities included overall evaluation of corporate asset values for purposes of divestiture or acquisition. Paul subsequently cofounded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., that is now one of Japan’s most successful orphan drug companies. As President of the U.S. division and a cofounder, he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.

As an adult-onset Type 1 diabetic, he knows firsthand how a patient can struggle to get the right diagnosis and treatment. Only 40,000 adults a year are diagnosed with Type 1 diabetes. Paul is actively involved in the Juvenile Diabetes Research Foundation (JDRF), an organization funding research for Type 1 diabetes.

Larry Zaslow co-founded BioTheryX, Inc along with three Celgene scientists, including David Stirling, co-founder of Celgene. BioTheryX is a leader in protein degradation technology. In addition to being a founder, Mr. Zaslow also served as a director, president, and key executive over a period of fifteen years. During his tenure at BioTheryX Mr. Zaslow had primary responsibility for critical areas including strategic and operational planning, capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals, investor and public relations. He helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies seeking to commercialize their intellectual property. He earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.

Theresa Heah has over two decades of global experience spearheading the development and commercialization of innovative therapies among early-staged, public-staged, and large pharmaceutical companies. An accomplished leader in the biotech industry, with a diverse background spanning small molecules, biologics, and gene therapies, Theresa has navigated successful M&A deals, venture capital fundraising, and the launch of groundbreaking products in various therapeutic areas. Her achievements include multiple regulatory approvals in the U.S., Europe, and Japan for revolutionary therapies like Ozurdex©, EYLEA©, Rhopressa©, and Rocklatan©. Dr. Heah holds a medical degree from King’s College London GKT School of Medicine , and an Executive MBA from the European School of Management & Technology (ESMT), Berlin. She currently serves as CEO and Board Member at Paratus Sciences.